Functional TK assays would represent an important tool for clinicians also for BCR-ABL1 CML and ALL: they could be used to guide the choice of TKI for the best target therapy and to identify primary TKI resistance in a timely manner at diagnosis. Here, TKT is linked to acute lymphoblastic leukemia.